Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 362 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Reference Product Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers

NCT03212677
View directory record Official record
Conditions
Iron
Interventions
Ferrous sulfate, IHAT, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
50 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

NCT02741739
View directory record Official record
Conditions
Healthy
Interventions
REGN1033
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

NCT06673641
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

NCT02789241
View directory record Official record
Conditions
Healthy
Interventions
Endotoxin, Placebo
Biological · Other
Lead sponsor
Robert J Noveck, M.D.
Other
Eligibility
18 Years to 40 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
Interventions
Laboratory Biomarker Analysis, Lapatinib, Lapatinib Ditosylate, Pharmacological Study, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 4 Interventional Results available

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227
View directory record Official record
Conditions
HIV, Combination Therapy
Interventions
Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 20, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo

NCT04685096
View directory record Official record
Conditions
Wrinkle, Fatigue, Puffiness Around the Eyes
Interventions
Test product creme, Reference creme
Other
Lead sponsor
Seneque SA
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Benazepril HCl 40 mg Tablets, Fasting

NCT00836576
View directory record Official record
Conditions
Healthy
Interventions
Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

NCT00744848
View directory record Official record
Conditions
Hemorrhoids
Interventions
Bupivacaine HCl, SKY0402
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Pasadena, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

NCT01149486
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide, Hyzaar®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted Conditions

NCT05674721
View directory record Official record
Conditions
Pain
Interventions
Advil PM Liqui-Gels Minis, Advil PM Liqui-Gels
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 55 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NCT02553161
View directory record Official record
Conditions
Depression, Anxiety, Bipolar Disorder
Interventions
Escitalopram, Cognitive behavioral Psychotherapy
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Stanford, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce

NCT00759954
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate sustained-release capsules, KADIAN (morphine sulfate sustained-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT02886715
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Tazorac®, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 20, 2026, 7:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept

NCT04529863
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Abatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.

NCT02923791
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Filgrastim Hospira, US-Approved Neupogen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Coral Gables, Florida • Jacksonville, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 20, 2026, 7:59 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

NCT04421885
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 20, 2026, 7:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope

NCT07136623
View directory record Official record
Conditions
Pulmnary Hypertension
Interventions
Eko CORE 500 phonocardiogram (PCG) recording, Eko CORE 500 three-lead electrocardiogram (ECG) recording
Diagnostic Test
Lead sponsor
Eko Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,513 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 7:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

NCT00759915
View directory record Official record
Conditions
Healthy
Interventions
morphine sulfate extended-release capsules, KADIAN (morphine sulfate extended-release) capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 20, 2026, 7:59 AM EDT